Achieve Life Sciences Promotes Jaime Xinos to Chief Commercial Officer to Advance Commercial Readiness of Cytisinicline
16 Oktober 2024 - 2:00PM
Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage
pharmaceutical company dedicated to the global development and
commercialization of cytisinicline for the treatment of nicotine
dependence, is pleased to announce the promotion of Ms. Jaime Xinos
to Chief Commercial Officer, effective immediately.
Ms. Xinos has been with Achieve Life Sciences since 2017,
serving as Executive Vice President of Commercial. In her expanded
role, she will oversee all commercial operations and lead the
company’s strategic preparations for the anticipated U.S. launch of
cytisinicline. This includes driving readiness across key
stakeholders, including patients, healthcare providers, and payors.
These efforts will help position cytisinicline for a successful
launch upon FDA approval.
Rick Stewart, CEO of Achieve Life Sciences, commented, “We are
thrilled to promote Jaime to Chief Commercial Officer, where she
will continue to build upon her leadership in driving our
commercial initiatives. Her focus on developing innovative,
patient-first, digital strategies is critical to our efforts to
successfully bring cytisinicline to market. Jaime’s leadership will
not only enhance cytisinicline’s commercial readiness but will also
be pivotal in helping millions of people struggling with smoking
and vaping addiction who are seeking new solutions to quit
following FDA approval.”
Ms. Xinos will spearhead Achieve’s efforts to forge strategic
partnerships with partners and commercialization experts with
proven experience that understand the unique challenges of small
biotech companies launching their first product and offer
value-driven, efficient solutions designed to ensure successful
market entry.
“I’m honored to step into this expanded role as Chief Commercial
Officer at such a pivotal time for Achieve Life Sciences,” said Ms.
Xinos. “Cytisinicline’s potential to become the first new
FDA-approved treatment for nicotine dependence in nearly two
decades offers an unparalleled opportunity to make a meaningful
impact on global public health. My focus will be on fostering
strong collaborations with key stakeholders and executing a
targeted, innovative strategy that can drive value while improving
the lives of the patients we serve.”
Ms. Xinos brings nearly 25 years of commercial experience in the
biotechnology and pharmaceutical industries, having held positions
of increasing responsibility at companies including OncoGenex,
Pfizer, Novartis, and Abbott Laboratories. She is recognized as an
inspirational thought leader, adept at translating scientific
advancements into business strategies and developing commercial
frameworks for specialty products across all stages of the product
lifecycle. Ms. Xinos holds a Bachelor of Arts (B.A.) in Liberal
Arts and Sciences and a Master of Business Administration (MBA)
both from the University of Illinois.
About Achieve and CytisiniclineAchieve’s focus
is to address the global smoking health and nicotine addiction
epidemic through the development and commercialization of
cytisinicline. There are approximately 29 million adults in the
United States alone who smoke combustible cigarettes.1 Tobacco use
is currently the leading cause of preventable death that is
responsible for more than eight million deaths worldwide and nearly
half a million deaths in the United States annually.2,3 More than
87% of lung cancer deaths, 61% of all pulmonary disease deaths, and
32% of all deaths from coronary heart disease are attributable to
smoking and exposure to secondhand smoke.3
In addition, there are over 11 million adults in the United
States who use e-cigarettes, also known as vaping.4 In 2024,
approximately 1.6 million middle and high school students in the
United States reported using e-cigarettes.5 Currently, there are no
FDA-approved treatments indicated specifically as an aid to
nicotine e-cigarette cessation.
Cytisinicline is a plant-based alkaloid with a high binding
affinity to the nicotinic acetylcholine receptor. It is believed to
aid in treating nicotine addiction for smoking and e-cigarette
cessation by interacting with nicotine receptors in the brain,
reducing the severity of nicotine craving symptoms, and reducing
the reward and satisfaction associated with nicotine products.
Cytisinicline is an investigational product candidate being
developed for the treatment of nicotine addiction and has not been
approved by the Food and Drug Administration for any indication in
the United States.
Forward Looking StatementsThis press release
contains forward-looking statements within the meaning of the “safe
harbor” provisions of the Private Securities Litigation Reform Act
of 1995, including, but not limited to, statements regarding the
timing and nature of cytisinicline clinical development and
regulatory review and approval, data results and commercialization
activities, the potential market size for cytisinicline, the
potential benefits, efficacy, safety and tolerability of
cytisinicline, the ability to discover and develop new uses for
cytisinicline, including but not limited to as an e-cigarette
cessation product, the development and effectiveness of new
treatments, and the successful commercialization of cytisinicline.
All statements other than statements of historical fact are
statements that could be deemed forward-looking statements. Achieve
may not actually achieve its plans or product development goals in
a timely manner, if at all, or otherwise carry out its intentions
or meet its expectations or projections disclosed in these
forward-looking statements. These statements are based on
management’s current expectations and beliefs and are subject to a
number of risks, uncertainties and assumptions that could cause
actual results to differ materially from those described in the
forward-looking statements, including, among others, the risk that
cytisinicline may not demonstrate the hypothesized or expected
benefits; the risk that Achieve may not be able to obtain
additional financing to fund the development and commercialization
of cytisinicline; the risk that cytisinicline will not receive
regulatory approval or be successfully commercialized; the risk
that new developments in the smoking cessation landscape require
changes in business strategy or clinical development plans; the
risk that Achieve’s intellectual property may not be adequately
protected; general business and economic conditions; risks related
to the impact on our business of macroeconomic and geopolitical
conditions, including inflation, volatile interest rates,
volatility in the debt and equity markets, actual or perceived
instability in the global banking system, global health crises and
pandemics and geopolitical conflict and the other factors described
in the risk factors set forth in Achieve’s filings with the
Securities and Exchange Commission from time to time, including
Achieve’s Annual Reports on Form 10-K and Quarterly Reports on Form
10-Q. Achieve undertakes no obligation to update the
forward-looking statements contained herein or to reflect events or
circumstances occurring after the date hereof, other than as may be
required by applicable.
Investor Relations ContactRich
Cockrellachv@cg.capital(404) 736-3838
Media ContactGlenn
SilverGlenn.Silver@Finnpartners.com(646) 871-8485
References 1VanFrank B, Malarcher A,
Cornelius ME, Schecter A, Jamal A, Tynan M. Adult Smoking Cessation
— United States, 2022. MMWR Morb Mortal Wkly Rep
2024;73:633–641. 2World Health Organization. WHO Report on the
Global Tobacco Epidemic, 2019. Geneva: World Health Organization,
2017. 3U.S. Department of Health and Human Services. The
Health Consequences of Smoking – 50 Years of Progress. A Report of
the Surgeon General, 2014. 4Cornelius ME, Loretan CG, Jamal A,
et al. Tobacco Product Use Among Adults – United States, 2021. MMWR
Morb Mortal Wkly Rep 2023;72:475–483. 5Park-Lee E, Jamal A,
Cowan H, et al. Notes from the Field: E-Cigarette and
Nicotine Pouch Use Among Middle and High School Students — United
States, 2024. MMWR Morb Mortal Wkly Rep 2024;73:774–778.
Achieve Life Sciences (NASDAQ:ACHV)
Historical Stock Chart
Von Nov 2024 bis Dez 2024
Achieve Life Sciences (NASDAQ:ACHV)
Historical Stock Chart
Von Dez 2023 bis Dez 2024